Zenas BioPharma’s (ZBIO) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Zenas BioPharma (NASDAQ:ZBIO) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $44.00 target price on the stock.

Other equities analysts also recently issued research reports about the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Zenas BioPharma in a research note on Tuesday, October 6th. Wedbush reaffirmed an “outperform” rating and set a $45.00 target price on shares of Zenas BioPharma in a research note on Wednesday, September 30th. Guggenheim reiterated a “buy” rating and set a $55.00 price target on shares of Zenas BioPharma in a report on Wednesday, September 30th. Citigroup increased their price target on Zenas BioPharma from $41.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, September 30th. Finally, Wall Street Zen upgraded Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $46.71.

Zenas BioPharma Stock Performance

ZBIO stock opened at $25.40 on Tuesday. The company has a debt-to-equity ratio of 1.57, a current ratio of 9.93 and a quick ratio of 9.93. Zenas BioPharma has a 12 month low of $13.50 and a 12 month high of $44.60. The firm has a 50-day moving average price of $30.31 and a 200-day moving average price of $25.46.

Zenas BioPharma (NASDAQ:ZBIO) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.65). The firm had revenue of $1.00 million for the quarter, compared to the consensus estimate of $15.00 million. Research analysts expect that Zenas BioPharma will post -5.81 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ZBIO. Quantbot Technologies LP acquired a new position in shares of Zenas BioPharma during the second quarter worth $49,000. Jupiter Topco LLC acquired a new stake in Zenas BioPharma in the second quarter valued at $201,000. The Manufacturers Life Insurance Company bought a new position in Zenas BioPharma during the 2nd quarter worth $204,000. Sei Investments Co. bought a new position in Zenas BioPharma during the 1st quarter worth $242,000. Finally, Engineers Gate Manager LP bought a new position in Zenas BioPharma during the 2nd quarter worth $329,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for patients with serious autoimmune diseases. The company’s research is centered on medicines designed to modulate the immune system while potentially avoiding the broad immune-cell depletion associated with some existing treatments.

Zenas’ lead product candidate is obexelimab, an investigational monoclonal antibody designed to bind CD19 and Fc?RIIb receptors on B cells. Through this mechanism, obexelimab is intended to inhibit B-cell activity without eliminating the cells.